The efficacy and safety of Remsima (subcutaneous) compared with Remsima (intravenous) in people with Crohn's disease and ulcerative colitis was assessed in an unpublished open-label randomised, phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback